The FDA approves Novartis' (NVS -0.5%) Afinitor for use in combination with Aromasin to treat...


The FDA approves Novartis' (NVS -0.5%) Afinitor for use in combination with Aromasin to treat certain postmenopausal women with advanced breast cancer. The drug combination is intended for use in women with recurrence or progression of their cancer after treatment with Femara or Arimidex.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs